CSMG Technologies Issues Letter to Shareholders Updating Live Tissue Connect Developments.

CORPUS CHRISTI, Texas -- CSMG Technologies President and CEO Donald S. Robbins today issued a letter to shareholders, updating the most recent development with subsidiary Live Tissue Connect.

Dear Shareholders:

We are extremely pleased to issue this update to report on several important milestones we have achieved over the last several months regarding the surgical human tissue welding technology, being developed by our Live Tissue Connect subsidiary.

On July 2, we reported that LTC filed a 510(k) submission with the U.S. Food and Drug Administration (FDA) for a human vessel and duct sealing electro-surgical generator, and two sealing instruments. A 510(k) filing seeks approval to sell medical devices in the U.S., a key market for LTC. In that announcement, we stated that information regarding procedures using the LTC technology, and technical information regarding the technology, was being removed from the CSMG web site pending FDA clearance. Currently we are working through the normal procedures of the US FDA approval process.

In late July, we announced a new domain name for CSMG's website, www.csmgtechinternational.com, for our international operations. A separate website for LTC, www.livetissueconnect.com is under construction and should be available within a few weeks.

We have started the certification process and are seeking to gain European market approval via a CE Mark certification before this year-end. We are anticipating having the above generator and instruments, which address several surgical procedures, in the European market by mid-2008 via various marketing arrangements.

Our strategy to maximize LTC revenues by forming five wholly-owned LTC medical procedure-specific subsidiaries, which we announced in May, is proving opportune and timely. In essence, we were certain that by creating five separate subsidiaries, we will maximize LTC's ability to enter into more lucrative and focused marketing agreements, partnerships, joint ventures, or other types of arrangements.

The targeted surgical specialty and the related newly-established subsidiaries are:

* Gynecology and General Surgery (GSG Medical Group)

* Orthopedics and Arthroscopy (Orthopedic Tissue Sciences)

* Colon Rectal Surgeries (Colorectal Connection Management)

* Pulmonary/Lung (Pulmonary Sealing Sciences)

* Urology (Urological Tissue Welding)

We are pleased to report that LTC is attracting interest from many significant medical device companies and distributors interested in representing, licensing, and/or marketing some aspect of the LTC technology. We believe each LTC wholly-owned subsidiary represents a distinct manufacturing, marketing, or licensing opportunity, and represents a major commercial opportunity for our company. We are confident this approach adds considerable value to the company.

Significantly, we also anticipate the first manufactured product meeting US and international standards to be available for sales and distribution prior to year end. To this purpose we have opened discussions with a number of independent distributors worldwide which is in addition to the aforementioned major medical device companies interested in licensing, distributing, manufacturing or marketing the product. In anticipation of the successful completion of these milestones we have started developing a highly experienced and well qualified LTC management, sales and distribution team.

Our LTC management team, along with our world-class medical device design and manufacturing partnerships in the U.S., coupled with our recent filing with the U.S. Food and Drug Administration, brings LTC's specialized medical device technology ever closer to the medical industry.

Looking forward, we have identified 12 procedure-specific divisions, but only established subsidiaries for the first five we regard as closest to product and market completion. This subsidiary structure should enable us to leverage LTC's R&D across multiple medical disciplines. As an example, the R&D effort that went into developing a sealing device for gynecological arteries and veins might be leveraged into a similar device for urological procedures though would likely be different in shape and/or size. This structure also lets potential marketing partner's select surgical specialties where they have strong physician relationships and/or pre-existing distribution channels.

On July 10, we announced, receipt of another tissue welding patent in Ukraine for "Method For Welding of Biological Tissue, Control Method For Welding Tissue (variants) and Apparatus For Biological Tissue Welding (variants)." This approval follows a similar U.S. patent which was already approved. The basic tissue welding science was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine in Kiev, which is headed by Professor B.E. Paton

LTC's surgical tissue bonding / welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC currently holds a total of approximately 40 patents in the U.S., Australia, Canada, European Union, and other countries.

Significantly, in June we announced that our Ukraine partner, International Association Welding ("IAW"), had received approval for surgical welding devices for sale in Russia. Approval was granted by the Russian Federal Service of Health Care and Social Development for a tissue welding electro surgery generator and eight instruments for use in Russian hospitals and clinics. The approval is for a wide range of procedures the electro-surgical tissue welding generator and ancillary instruments can perform.

Our press release issued on July 25 2007, entitled "CSMG Technologies Reviews Last 12 Months at Empire Financial Group Conference" addresses milestones and highlights achieved over the prior year. It may be read in its entirety at http://www.csmgtechinternational.com/news/press_072507.html. We continue to work with Empire Financial Group (AMEX: EFH), our investment banker, to assist us in corporate finance.

Management of the company is aggressively and tirelessly focused on developing and implementing strategies that will quickly, efficiently, and most profitably deliver the LTC surgical technology to markets worldwide.

For more complete, detailed information about CSMG Technologies, please access our website: www.csmgtechinternational.com.

We will continue to keep you apprised of our progress as we reach additional milestones. In closing, I want to express management's appreciation and thanks for the continuous support of our shareholders and the investment community. We will continue to strive to exceed your expectations for CSMG and Live Tissue Connect.

Thank you.

Donald S. Robbins

Chairman/ CEO

CSMG Technologies, Inc.

701 North Tower

500 N. Shoreline

Corpus Christi, TX 78471

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.